^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PTPA (Protein phosphatase 2 phosphatase activator)

    i
    Other names: PTPA, Protein Phosphatase 2 Phosphatase Activator, Phosphotyrosyl Phosphatase Activator, Serine/Threonine-Protein Phosphatase 2A Regulatory Subunit B', Protein Phosphatase 2A Activator, Regulatory Subunit 4, Protein Phosphatase 2A, Regulatory Subunit B' (PR 53), Serine/Threonine-Protein Phosphatase 2A Activator, Protein Phosphatase 2 Regulatory Subunit 4, PP2A Phosphatase Activator, PPP2R4, PR53, Serine/Threonine-Protein Phosphatase 2A Regulatory Subunit 4, Protein Phosphatase 2A Regulatory Subunit 4, PP2A, Subunit B', PR53 Isoform, PP2A
    over1year
    Increased ONECUT2 induced by Helicobacter pylori promotes gastric cancer cell stemness via an AKT-related pathway. (PubMed, Cell Death Dis)
    This study highlights a critical role played by ONECUT2 in promoting HP infection-associated GC by enhancing cell stemness through the PPP2R4/AKT/β-catenin signaling pathway. These findings suggest promising therapeutic strategies and potential targets for GC treatment.
    Journal
    |
    PTPA (Protein phosphatase 2 phosphatase activator) • ONECUT2 (One Cut Homeobox 2)
    over3years
    Peptide PDHPS1 inhibits ovarian cancer growth through disrupting YAP signaling. (PubMed, Mol Cancer Ther)
    Besides, modification of membrane penetration could improve the physicochemical properties and biological activity of PDHPS1. In conclusion, our study demonstrated that the endogenous peptide PDHPS1 serves as an anti-tumor peptide to inhibit YAP signaling pathway though interacting with PTPA in ovarian cancer.
    Journal
    |
    PTPA (Protein phosphatase 2 phosphatase activator)
    over4years
    PPP2R4 dysfunction promotes KRAS-mutant lung adenocarcinoma development and mediates opposite responses to MEK and mTOR inhibition. (PubMed, Cancer Lett)
    A confined kinase inhibitor screen revealed that PPP2R4-depletion induced resistance against selumetinib (MEK inhibitor), but unexpectedly sensitized cells for temsirolimus (mTOR inhibitor), in vitro and in vivo. Our findings underscore a clinically relevant role for PTPA loss-of-function in KRAS-mutant NSCLC etiology and kinase inhibitor response.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • PTPA (Protein phosphatase 2 phosphatase activator)
    |
    KRAS mutation • KRAS G12D • KRAS G12 • MYC expression • KRAS expression
    |
    Koselugo (selumetinib) • temsirolimus